Replies to post #33988 on Revive Therapeutics Ltd (RVVTF)

[rickstereo3333]

An Accurate Revive vs Relief Comparison...............



TRIALS:
Revive - Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients With Mild-Moderate COVID-19
Relief - Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19 (AVICOVID-2)


TRIAL STATUS:
Revive - Submissions before FDA for consideration (Ongoing)
Relief - EUA request Rejected


SHARE STRUCTURE:
Revive - ~350 Million
Relief - 4.4 Billion



I could go on further but the criteria cited above adequately exposes the false equivalence being made.

[Ecomike]

LOL, so it is not impossible. Thanks for confirming that:

"The FDA agreed to let Rlftf change their primary endpoint."

So all BS on Reddit was just that, BS. FDA has done it before, and has allowed it.

So it is not even a high risk of asking for something that has never been done. Because it has been done before.

In this case, the reason for changing it is because the Virus changed, and the medical need to modify the course of the disease changed during the study...

So it makes perfect sense to change the end point... Or to at least ask the FDA if they like the idea....in a meeting...